IRB #

IRB00011462

Title

A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator

Khaled Tolba

Study Purpose

To find out if the combination of serlumetinib (the study drug) and taxol is safe and tolerable for patients with non-small cell lung cancer (NSCLC).

Medical Condition(s)

NSCLC

Eligibility Criteria

1. Male or female age 18 or older
2. Confirmed Stage IIIB - IV non-small cell lung cancer
3. Must have received and failed first-line therapy for NSCLC
4. Adequate bone marrow and liver function
5. Estimated life expectancy of 12 weeks or more
6. Other eligibility criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drugs until disease progression or development of intolerable side effects. All participants will be contact by phone every 8 weeks after their last dose of study drugs in the first year, and then every 3 months after that.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

OHSU Knight Cancer Institute

Recruitment End

12/31/2017

Compensation Provided

No


Go Back